Stockscreener 앱 받기
34.18
1.56%
-0.54
전일 마감가:
$34.72
열려 있는:
$34.39
하루 거래량:
476.12K
Relative Volume:
0.22
시가총액:
$4.03B
수익:
$1.29B
순이익/손실:
$251.00M
주가수익비율:
17.31
EPS:
1.9744
순현금흐름:
$-193.86M
1주 성능:
-1.75%
1개월 성능:
-7.32%
6개월 성능:
-0.73%
1년 성능:
+37.21%
1일 변동 폭
$33.84
$34.60
1주일 범위
$33.93
$35.36
52주 변동 폭
$24.28
$42.81
Indivior Pharmaceuticals Inc Stock (INDV) Company Profile
명칭
Indivior Pharmaceuticals Inc
전화
804-379-1090
주소
10710 MIDLOTHIAN TURNPIKE, NORTH CHESTERFIELD
Compare INDV vs TAK, TEVA, HLN, ZTS, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INDV
Indivior Pharmaceuticals Inc
|
34.18 | 4.03B | 1.29B | 251.00M | -193.86M | 1.9744 |
TAK
Takeda Pharmaceutical Co Adr
|
20.12 | 64.26B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.94 | 46.58B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.04 | 44.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
77.45 | 32.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
584.96 | 25.09B | 3.17B | 1.29B | 1.01B | 27.09 |
Indivior Pharmaceuticals Inc Stock (INDV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-06-18 | 개시 | Barclays | Overweight |
| 2025-08-06 | 개시 | H.C. Wainwright | Buy |
| 2025-07-22 | 재개 | Jefferies | Buy |
| 2025-01-28 | 개시 | Rodman & Renshaw | Buy |
| 2024-07-23 | 개시 | Piper Sandler | Overweight |
| 2024-04-03 | 개시 | Craig Hallum | Buy |
| 2023-07-13 | 개시 | Northland Capital | Outperform |
모두보기
Indivior Pharmaceuticals Inc 주식(INDV)의 최신 뉴스
Indivior Pharmaceuticals, Inc. (INDV) Stock Price, News, Quote & History - Yahoo! Finance Canada
Third-quarter results are due at 7 a.m. Oct. 29 from Indivior. - Stock Titan
With 77.27% of shares represented, Indivior (INDV) stockholders vote on merger-related share issuance. - Stock Titan
A $1B special dividend features in Indivior (INDV)'s revised merger valuation details. - Stock Titan
Indivior stock pre-market at EUR 32.10: plus 0.00 percent - AD HOC NEWS
Global Substance Use Disorder Treatment Market Analysis and Forecast to 2030 | Long-Acting Therapies, Telemedicine, and Drug Innovation Drive Growth - GlobeNewswire Inc.
Halper Sadeh LLC is Investigating Whether ITGR, FHB, INDV, LNTH are Obtaining Fair Deals for their Shareholders - GlobeNewswire Inc.
Three parties report a passive holding above 5% in Indivior (INDV). - Stock Titan
Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.SUPN - Business Wire
Indivior (NASDAQ: INDV) Announces Conditional $8.13 Special Dividend Pending Merger Completion - Kalkine Media
Indivior Declares $8.13 Per Share Special Dividend Tied to Supernus Merger Closing - Minichart
An $8.13 cash payout at Indivior (INDV) hinges on a merger closing - Stock Titan
Indivior declares $8.13 special dividend contingent on merger - Investing.com India
Indivior Pharmaceuticals, Inc. Declares Special Cash Dividend - Indivior
Indivior Pharmaceuticals Declares $8.13 Special Cash Dividend Contingent on Supernus Merger Closing - Quiver Quantitative
Indivior declares $8.13 special dividend contingent on merger - Investing.com
Indivior Pharmaceuticals, Inc. SEC Filing (Sep 14, 2026) - Stock Titan
$1 billion dividend hangs on Supernus (NASDAQ: SUPN) merger vote - Stock Titan
Indivior stock gains as Supernus merger and special dividend plan come into focus - ad-hoc-news.de
Indivior (INDV) plans special dividend if Supernus merger closes, with two payout structures - Stock Titan
SUPN: Strong CNS portfolio growth, innovative pipeline, and Indivior merger set to drive future expansion - TradingView
Indivior stock gains on raised 2026 guidance and Supernus deal - ad-hoc-news.de
Indivior stock rises on strong Q2 2026 earnings and higher full-year guidance - AD HOC NEWS
Indivior stock gains on raised 2026 outlook and strong Sublocade growth - AD HOC NEWS
Indivior Pharmaceuticals Inc. (INDV) Down 5.3% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Price to earnings forward of Indivior Pharmaceuticals, Inc. – NASDAQ:INDV - TradingView
Indivior Pharmaceuticals Inc. (INDV) Loses 12.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indiv - The National Law Review
INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - FinancialContent
Indivior stock trades below fair value as latest earnings beat expectations - AD HOC NEWS
Why Indivior Pharmaceuticals (INDV) Is Back In The Spotlight - sahmcapital.com
Indivior Pharmaceuticals CAO Woodrow D. Anderson Acquires 1,500 Shares at $35.69 Each - Kalkine Media
Indivior (INDV) accounting chief adds 1,500 shares in market or private buy - Stock Titan
Indivior Pharmaceuticals (INDV) Could Be 30% Undervalued On Its Cost Reset Plan - Yahoo Finance
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Barchart.com
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - Yahoo Finance
Should Investors Buy INDV as Sublocade Growth Meets Rising Risks? - Yahoo Finance
Indivior's Supernus Merger Could Broaden Its Growth Engine in 2026 - theglobeandmail.com
Indivior Pharmaceuticals Inc (INDV) Shares Fall 3.3% -- GF Value Says Still Overvalued - GuruFocus
Indivior stock steadies after Supernus merger deal highlights $2.2 billion revenue goal - ad-hoc-news.de
Indivior stock edges higher as options activity and analyst targets point to further upside - Ad-hoc-news.de
Indivior Q2 2026 Earnings Call: Complete Transcript - Sahm
Indivior Q2 2026 Earnings Call: Complete Transcript - Benzinga
Indivior (INDV) Gains 2.07% to $39.01 as Opioid Addiction Treatment Demand Lifts Pharma StockBreakout Trade - vinanet.vn
Indivior Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:INDV - TradingView
Is Indivior Pharmaceuticals (INDV) Below Fair Value Despite A 194% Return? - webull.com
Indivior Pharmaceuticals, Inc. Revenue Breakdown – FWB:E7P - TradingView
Oaktree trims Indivior (INDV) holdings, files Schedule 13D exit amendment - Stock Titan
Indivior Pharmaceuticals, Inc. (INDV) Options Chain - Yahoo! Finance Canada
Morgan Lewis Advises Supernus Pharmaceuticals on Merger with Indivior Pharmaceuticals – News - Morgan Lewis
Indivior Pharmaceuticals Inc (INDV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Indivior Pharmaceuticals Inc 주식 (INDV) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Anderson Woodrow D | Chief Accounting Officer |
Aug 05 '26 |
Buy |
36.28 |
1,500 |
54,420 |
26,138 |
| Heidbreder Christian | Chief Scientific Officer |
Jul 10 '26 |
Sale |
41.14 |
18,586 |
764,628 |
209,337 |
| Heidbreder Christian | Officer |
Jul 10 '26 |
Proposed Sale |
41.14 |
18,586 |
764,628 |
0 |
| Heidbreder Christian | Officer |
Jun 11 '26 |
Proposed Sale |
38.06 |
18,586 |
707,383 |
0 |
| Heidbreder Christian | Chief Scientific Officer |
Jun 11 '26 |
Sale |
38.06 |
18,586 |
707,383 |
227,923 |
| Preblick Ryan | Chief Financial Officer |
Jun 08 '26 |
Sale |
37.70 |
36,000 |
1,357,200 |
284,751 |
| Preblick Ryan | Officer |
Jun 08 '26 |
Proposed Sale |
37.70 |
36,000 |
1,357,200 |
0 |
| Ryan Barbara | Director |
Mar 13 '26 |
Buy |
31.09 |
8 |
249 |
5,724 |
| Ryan Barbara | Director |
Mar 09 '26 |
Buy |
32.56 |
31 |
1,009 |
5,716 |
| Kingsley Stuart A | Director |
Mar 06 '26 |
Buy |
31.86 |
940 |
29,953 |
5,582 |
2.95%
1.55%
자본화:
|
볼륨(24시간):